Clinical Trial Update: Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis [Phase 2]

View source ↗

Summary

A Phase 2 trial update reports results for saroglitazar magnesium in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Results were posted on 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Saroglitazar Magnesium (saroglitazar magnesium)

Snippet

Sponsor: Zydus Therapeutics Inc. | Conditions: Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2024-10-24